BREAKING NEWS: Wall Street Journal article puts spotlight on the potential of new anticoagulants taking fresh aim at one of cardiology’s toughest challenges.

February 9, 2023

Evaluating Evolving Approaches to Treating Thrombosis in Cancer


Accredited CME Program


Jean M. Connors, MD
Medical Director, Hemostatic Antithrombotic Stewardship
Medical Director, Anticoagulation Management Services (Hematology Division)
Brigham and Women’s Hospital/Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts, United States




AlokA. Khorana, MD
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Sondra and Stephen Hardis Chair in Oncology Research
Vice Chair, Clinical Services
Director, Gl Malignancies Program
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio, United States
Jeffrey l. Weitz, MD, FRCP(C), FACP, FCCP
Professor of Medicine and Biochemistry
McMaster University
Hamilton, Ontario, Canada


Slide presentation: Evaluating Evolving Approaches to Treating Thrombosis in Cancer SLIDE


Burden of Cancer-Associated Thrombosis


Cancer-Associated Thrombosis = Arterial Venous Thrombosis


Mechanism of Thrombosis is Different in Cancer Patients


Choosing Between the Agents


CLOT Trial and the FDA-Approved LMWHs


Choosing Between the Agents


Choosing Between the Agents


Guideline Recommendations for Treatment of CAT-VTE


Weighing the Treatment Options


Considerations for Anticoagulation Therapy in Cancer Patients




Finding the Right Therapy


Treatment Individualization and Shared Decisions


Though LMWH Is Preferred for High Risk of Bleeding…
Adherence/Treatment Persistence is an Issue


Limitations of Standard Care

Data from RCTs Comparing DOACs and LMWH in CAT

Why Target Factor XI?
Anticoagulants, Hemostasis, and Thrombosis


Uncoupling Thrombosis From Hemostasis


Targeting the Instrinsic Pathway


Clotting Cascade
Factor XI Targets


Phase 3 Clinical Trials Targeting Factor XI for CAT


Emerging Clinical Trials Targeting Factor XI – Phase 3


Other Studies Targeting Factor XI


Uncoupling Thrombosis from Homeostasis: Future Uses


Concluding Remarks